Immunotherapy has emerged as a promising treatment paradigm for many malignancies
and is transforming the drug development landscape. Although immunotherapeutic agents …

For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

In the absence of cell surface cancer-specific antigens, immunotherapies such as chimeric
antigen receptor (CAR) T cells, monoclonal antibodies, or bispecific T cell engagers typically …

Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic
malignancies, but its application to solid tumors has been challenging,,–. Given the unique …

FTO, an mRNA N 6-methyladenosine (m 6 A) demethylase, was reported to promote
leukemogenesis. Using structure-based rational design, we have developed two promising …

Autologous induced pluripotent stem cells (iPSCs) constitute an unlimited cell source for
patient-specific cell-based organ repair strategies. However, their generation and …

Human intestinal organoids (HIOs) derived from pluripotent stem cells provide a valuable
model for investigating human intestinal organogenesis and physiology, but they lack the …

Summary R-2-hydroxyglutarate (R-2HG), produced at high levels by mutant isocitrate
dehydrogenase 1/2 (IDH1/2) enzymes, was reported as an oncometabolite. We show here …

Neutrophils, the most abundant innate immune cells, function as crucial regulators of the
adaptive immune system in diverse pathological conditions, including metastatic cancer …

Summary N 6-methyladenosine (m 6 A), the most prevalent internal modification in
eukaryotic messenger RNAs (mRNAs), plays critical roles in many bioprocesses. However …